ESCRS - FPT02.07 - Plasma Rich In Growth Factor Vs Mitomycin C In Photorefractive Keratectomy

Plasma Rich In Growth Factor Vs Mitomycin C In Photorefractive Keratectomy

Published 2022 - 40th Congress of the ESCRS

Reference: FPT02.07 | Type: Free paper | DOI: 10.82333/jbdc-eq69

Authors: Edmar Uribe* 1 , Jesus Merayo 2 , Ronald Sanchez 2

1Corneal and External disease - Uveitis,Instituto Unversitario Fernandez Vega - Universidad de Oviedo,Oviedo,Spain;Corneal and external disease - Uveitis,Clinica Delgado,Lima,Peru;Universidad San Martin de Porres,Lima,Peru, 2nstituto Unversitario Fernandez Vega - Universidad de Oviedo,Oviedo,Spain

Purpose

To evaluate the efficacy and safety of Plasma Rich in Growth Factors (PRGF) in prevention of corneal haze in patients undergoing PRK  surgery and the comparison with the use of mitomycin c

Setting

Fernandez Vega University Institute - Eye Surface Unit  ( IUFV) Oviedo-Spain

Methods

 

This retrospective study included patients of the consultation of IUFV (Fernández-Vega University Institute) Corneal Unit between 2013 and 2016 who underwent PRK surgery.
They have spherical correction range from -0.25 to -8.00 D, cylinder correction range from -0.25 to -3.00 and refraction stability at least 1 year.

The mitomycin C was used in 0.02% concentration, 10 seconds per Diopter treated with maximum of 40 seconds and PRGF follow the Endoret System protocol, having contact with the surface for a minute in all cases.

 

Primary endpoint was evaluate and compare the efficacy and safety on both treatments, The adverse events also were reported.  

Results

69 patients of 117 eyes were included in the study. 44 patients (72 eyes) were treated with MMC and 25 patients (45 eyes) with PRGF. There were no statistically significant difference in previous CDVA, sphere, cylinder or EE between the groups.


The average corneal  ablation was 29.3 ± 12.6 µm, and the remanent stroma was 491.4 ± 44.5 µm. The epithelization time was 63.7 ± 12.3 hours and UDVA(LogMAR) was 0.029 ± 0.059, there was not statistically significant difference between the treatments.


The corneal endothelial cell density in both groups was very similar (p = 0.054), there was no was statistically significant difference between treatments in efficacy (p = 0.062) and security (p =0.158)


There was no reports of  adverse effects in the study

Conclusions

The use of PRGF in prevention of corneal opacity is  as effective and safe as Mitomicin C, with no recurrence or corneal haze in one year of follow up